AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00108615 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CT scans
Description: To measure changes in adipose tissue volumes
Study NCT00108615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test
Description: To detect a change in glucose tolerance
Study NCT00108615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: To detect a change in glucose tolerance
Study NCT03583112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxetine Hydrochloride Tablet
Description: oral one dapoxetine hydrochloride tablet before MRI scan
Study NCT03583112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: oral one placebo tablet before MRI scan.
Study NCT00655239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroadaptive cognitive training
Description: Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
Study NCT00655239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuroadaptive cognitive training
Description: Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
Study NCT00655239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer games
Description: The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
Study NCT03231228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 1 g Infusion
Description: 1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to \<60 kg
Study NCT03231228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 2 g Infusion
Description: 2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
Study NCT00469040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444M for 14 days
Description: M salt
Study NCT05010395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter intervention
Description: Letter intervention
Study NCT03139435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo skin biopsy
Study NCT03139435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03139435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Tomography
Description: Undergo peripheral nerve ultrasound
Study NCT02812394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301 (Dose Level 1)
Description: All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.
Study NCT02812394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301 (Dose Level 2)
Description: All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.
Study NCT02812394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet®
Description: All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
Study NCT00024206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orantinib
Description: Given orally
Study NCT00024206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00024206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02072733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive geriatric assessment
Description: Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
Study NCT06343129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary education program
Description: Jumpstart educational program:~https://www.rochesterlifestylemedicine.com/about-community-jumpstart/
Study NCT02896751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed NIV mask
Description: use of 3D printed mask
Study NCT02365506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Tablets administered orally in a single dose
Study NCT02365506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match tablets administered orally in a single dose
Study NCT02365506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match tablets administered orally in a single dose
Study NCT01174940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extracorporeal photopheresis
Description: Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient.
Study NCT03858686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP-025 capsules
Description: FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
Study NCT03858686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FP-025 capsules
Description: FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
Study NCT03858686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FP-025 capsules
Description: Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
Study NCT03858686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FP-025 capsules
Description: Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
Study NCT02038790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone Sublingual Film
Description: A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
Study NCT02111915 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THPP-P
Description: Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
Study NCT02038790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zubsolv sublingual tablets
Description: A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
Study NCT03649386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated and humidified breathing circuit on
Description: Heated and humidified breathing circuit will be turned on.
Study NCT03649386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated and humidified breathing circuit off
Description: Heated and humidified breathing circuit will be turned off.
Study NCT01512329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pacing
Description: 3 one-on-one sessions weekly for 3 consecutive weeks
Study NCT01512329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation
Description: 3 one-on-one sessions weekly for 3 consecutive weeks
Study NCT06330766 — intervention group
Intervention type: PROCEDURE
Intervention: No preoperative dental screening
Description: Discontinuance of mandatory preoperative dental screening prior TAVI which also can include oral surgery.
Study NCT02071329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine FP-01.1
Study NCT02071329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02071329 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Virus Challenge
Study NCT02071329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virus Challenge
Study NCT02725749 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
Study NCT02725749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EXE
Description: Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks.
Study NCT02725749 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Laser + EXE
Description: Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks.
Study NCT03371589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Solution for otic injection
Study NCT03364062 — intervention group
Intervention type: PROCEDURE
Intervention: cemented shoulder replacement
Description: proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
Study NCT02296229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study NCT02296229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT02296229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02296229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Description: up to 9 months at the discretion of the treating physician
Study NCT01003067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh implementation
Description: Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
Study NCT04574674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility exercise programme
Description: Static passive flexibility exercises.
Study NCT04574674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise programme
Description: Body weight and resistance bands exercises.
Study NCT02174809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of 5As to discuss gestational weight gain
Study NCT02174809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT00610714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0530
Description: oral once daily dose
Study NCT00610714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous injection
Study NCT00610714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: intravenous injection
Study NCT00610714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: intravenous infusion
Study NCT00610714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: intravenous infusion
Study NCT03973567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants
Description: On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
Study NCT03973567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional therapy
Description: Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
Study NCT04019197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product
Description: semaglutide subcutaneous injection
Study NCT04019197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo injection
Study NCT02057276 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
Study NCT02057276 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Study NCT02057276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Study NCT02057276 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Occupational Therapy
Study NCT02837055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight intubation
Description: patients are intubated with an endotracheal tube with an integrated camera
Study NCT02837055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional intubation
Description: patients are intubated with a conventional endotracheal tube
Study NCT02869451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: Prescribed one week prior to quit and continued until the 6 month follow-up visit.
Study NCT02869451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch
Description: Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
Study NCT02869451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Initiated at smoking quit date.
Study NCT02869451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine lozenge
Description: Initiated at smoking quit date.
Study NCT02869451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling for marijuana and smoking cessation
Description: 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
Study NCT02869451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile contingency management
Description: treatment that provides money rewards for abstinence from smoking and marijuana
Study NCT03908463 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: All coronary intervention procedures will be performed according to current standard techniques.
Study NCT04437602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Mammography (CEM)
Description: Additional CEM in preoperative staging
Study NCT03628391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
Study NCT03628391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo for ICU delirium, titrated on validated screening tool-based diagnosis
Study NCT04367649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hall technique
Description: * Orthodontic separators will be used to create space for fitting the stainless crown, then removed after 3-5 days~* Occlusion will be measured assessing the patient's occlusal-vertical dimensions (OVD) using a modified version of van der Zee and van Amerongen method with a millimeter probe measuring the distance from the lowest point of the gingiva, around the lower canine on the vestibular side up to the point where the tip of the upper canine ends in order to assess the degree of overbite after mounting of the crown.~* The correct crown size will be selected. The crown should cover all the cusps and approaches the contact points, with a slight feeling of spring back. till reaching the gingival margin. Cementation will be done using glass ionomer cement
Study NCT04367649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic restorative treatment
Description: Caries removal using excavators, then restoration using glass ionomer (GIC)
Study NCT04367649 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional restorative treatment
Description: Complete caries removal using high-speed hand piece, and an excavator to clear carious dentin from the pulpal wall. Then, stainless steel crown preparation, selection of the proper size with the smallest crown size that completely covers the preparation chosen. The correct occlusogingival crown length will be established. Cementation will be done using glass ionomer cement
Study NCT02094664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated and humidified oxygen
Study NCT02111915 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EUC
Description: EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
Study NCT02111915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EUC
Description: EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
Study NCT03043690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Ammonium succinate
Description: 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
Study NCT03043690 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
Study NCT03178825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Fractional Laser
Description: Consecutive and coincident fractional 2940 nm and 1470 nm lasers
Study NCT00302172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted.
Study NCT04556591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive intervention (JITAI)
Description: JITAI is an emerging intervention that incorporates passive mobile sensor data feedback (sleep and activity \[step\] data from a Fitbit ®), and real-time self-reporting of HRQOL via a study specific app called CareQOL to provide personalized feedback via app alert.
Study NCT04556591 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will wear the Fitbit® and provide daily reports of HRQOL over a three-month (90 day) period